SCHEMBL2496975

SCHEMBL2496975

COC(=O)C(F)(F)c1ccc2ncccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ NPC1 O15118 6/20 0.49
▸ RAB9A P51151 5/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ PLK1 P53350 1/20 0.49
▸ POLB P06746 3/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ PABPC1 P11940 1/20 0.46
▸ TRPM8 Q7Z2W7 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.43
▸ TAS1R1 Q7RTX1 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MET P08581 2/20 0.42
▸ BRAF P15056 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ PDGFRA P16234 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2698588 0.88 ALOX15 (0.55) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL9924303 0.85 HTT (0.50) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL1163211 0.85 ACSS2 (0.52) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL3603329 0.84 ALOX15 (0.57) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL2698205 0.82 PABPC1 (0.50) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL1163268 0.82 NPC1 (0.49) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL2695441 0.82 ALOX15 (0.48) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL3001120 0.81 ALOX5 (0.46) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL30421806 0.81 NPC1 (0.48) ALOX15HTTNPC1RAB9AALDH1A1
SCHEMBL9910478 0.81 NPC1 (0.48) ALOX15HTTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966214-B9 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-13 — — EP disclosed
EP-1966214-B9 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-13 — — EP disclosed
EP-2231663-B1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS AMGEN INC (US) 2017-08-02 — — EP disclosed
EP-2231663-B1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS AMGEN INC (US) 2017-08-02 — — EP disclosed
EP-3170824-A1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS Amgen, Inc (US) 2017-05-24 — — EP disclosed
EP-3170824-A1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS Amgen, Inc (US) 2017-05-24 — — EP disclosed
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 — — EP disclosed
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 — — EP disclosed
EP-1966214-B1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-02 — — EP disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 — — EP disclosed
US-20090098181-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-16 — — US disclosed
US-20090098181-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-16 — — US disclosed
EP-1966214-A1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS Janssen Pharmaceutica, N.V. (BE) 2008-09-10 — — EP disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 — — WO disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 — — WO disclosed
US-20070203136-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-30 — — US disclosed
US-20070203136-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-30 — — US disclosed
US-20070203136-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-30 — — US disclosed
WO-2007075567-A1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-05 — — WO disclosed
WO-2007075567-A1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203136-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS RET, MET, ABL1 ALOX15 4241/4885HTT 3089/4885NPC1 2652/4885
US-20090098181-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS RET, MET, ABL1 ALOX15 4241/4885HTT 3089/4885NPC1 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback